Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

NCT03288480 is registered in ClinicalTrials.gov with Promontory Therapeutics Inc. as lead sponsor.

NCT NCT03288480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Promontory Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 15, 2017
Completion date
March 1, 2021
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma